浙江医药
(600216)
| 流通市值：89.43亿 | | | 总市值：89.74亿 |
| 流通股本：9.62亿 | | | 总股本：9.65亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,876,518,447.27 | 3,937,942,897.55 | 2,007,935,140.53 | 8,115,804,648.33 |
| 营业收入 | 5,876,518,447.27 | 3,937,942,897.55 | 2,007,935,140.53 | 8,115,804,648.33 |
| 二、营业总成本 | 5,607,285,954.16 | 3,702,739,461.73 | 1,902,448,267.47 | 7,482,025,427.21 |
| 营业成本 | 3,903,509,995.66 | 2,605,226,938.66 | 1,330,219,880.04 | 5,318,274,426.32 |
| 税金及附加 | 53,539,115.05 | 33,566,826.88 | 16,262,945.52 | 69,862,910.12 |
| 销售费用 | 755,074,640.99 | 468,865,070.02 | 271,974,096.37 | 890,508,132.92 |
| 管理费用 | 308,718,579.07 | 198,449,307.21 | 105,835,577.77 | 432,066,700.89 |
| 研发费用 | 607,134,841.28 | 430,102,351.06 | 166,709,820.29 | 809,279,317.22 |
| 财务费用 | -20,691,217.89 | -33,471,032.1 | 11,445,947.48 | -37,966,060.26 |
| 其中:利息费用 | 21,282,957.96 | 14,409,347.12 | 7,203,313.92 | 33,170,102.05 |
| 其中:利息收入 | 12,584,586.89 | 8,130,371.02 | 2,530,101.72 | 13,176,958.6 |
| 加:公允价值变动收益 | -4,714,569.07 | 5,315,635.26 | 11,310,125.76 | -23,881,330.47 |
| 加:投资收益 | -603,058.29 | 2,705,548.93 | 3,118,443.22 | -32,625,966.33 |
| 资产处置收益 | -752,178.79 | -62,488.31 | -25,198.61 | 3,309,480.04 |
| 资产减值损失(新) | -64,500,663.9 | -34,422,727.59 | -13,615,292.64 | -117,141,414.11 |
| 信用减值损失(新) | 17,385,441.58 | 22,751,501.94 | -8,629,019.36 | -25,088,386.86 |
| 其他收益 | 43,206,763.33 | 21,325,743.3 | 7,656,564.09 | 66,264,351.33 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 259,254,227.97 | 252,816,649.35 | 105,302,495.52 | 504,615,954.72 |
| 加:营业外收入 | 24,464,480.65 | 24,326,258.06 | 170,021.27 | 2,126,365.27 |
| 减:营业外支出 | 15,336,121.69 | 14,227,809.23 | 3,109,669.5 | 15,353,899.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 268,382,586.93 | 262,915,098.18 | 102,362,847.29 | 491,388,420.68 |
| 减:所得税费用 | 87,516,878.61 | 75,914,587.62 | 18,290,631.21 | 128,774,678.73 |
| 六、净利润 | 180,865,708.32 | 187,000,510.56 | 84,072,216.08 | 362,613,741.95 |
| 持续经营净利润 | 180,865,708.32 | 187,000,510.56 | 84,072,216.08 | 362,613,741.95 |
| 归属于母公司股东的净利润 | 301,338,595.24 | 272,261,125.88 | 113,551,849.15 | 539,570,083.23 |
| 少数股东损益 | -120,472,886.92 | -85,260,615.32 | -29,479,633.07 | -176,956,341.28 |
| (一)基本每股收益 | 0.31 | 0.28 | 0.12 | 0.56 |
| (二)稀释每股收益 | 0.31 | 0.28 | 0.12 | 0.56 |
| 八、其他综合收益 | 5,759,087.09 | 13,968,045.4 | 1,258,936.9 | 9,419,617.42 |
| 归属于母公司股东的其他综合收益 | 5,482,416.32 | 13,260,059.25 | 1,208,686.09 | 8,720,202.35 |
| 九、综合收益总额 | 186,624,795.41 | 200,968,555.96 | 85,331,152.98 | 372,033,359.37 |
| 归属于母公司股东的综合收益总额 | 306,821,011.56 | 285,521,185.13 | 114,760,535.24 | 548,290,285.58 |
| 归属于少数股东的综合收益总额 | -120,196,216.15 | -84,552,629.17 | -29,429,382.26 | -176,256,926.21 |
| 公告日期 | 2023-10-26 | 2023-08-24 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |